COVID-19 drugs to be reimbursable, "KRW 50,000 co-payment"
By Lee, Jeong-Hwan | translator Hong, Ji Yeon
24.09.27 05:40:34
가나다라
0
Paxlovid and Veklury will be reimbursable…reimbursement coverage for Zejula will be expanded
Extended NHI support for emergency care, costing KRW 208.5 billion per month
The government will list COVID-19 treatments for reimbursement and make a policy revision to support the patient co-payment at the previous price of KRW 50,000.
The National Health Insurance coverage for Takeda Pharmaceuticals Korea's Zejula Cap (ingredient: niraparib tosylate monohydrate), a treatment for advanced ovarian cancer, will be expended, and the ceiling price of the drug will be reduced, starting on October 1st.
Patients with advanced ovarian cancer who paid KRW 41 million in annual treatment costs per person are expected to pay KRW 2..05 million in
Lee, Jeong-Hwan(junghwanss@dailypharm.com)
If you want to see the full article, please JOIN US (click)